FDA product code QUE: Spinal Muscular Atrophy Newborn Screening Test System

QUE is the FDA product code for spinal muscular atrophy newborn screening test system. It is a Class II device, regulated under 21 CFR 866.5980 and reviewed by the Medical Genetics panel. FDA has cleared 1 510(k) submission under QUE, 1 in the last five years. The average 510(k) review took 44 days (median 44); 44 days on average over the last three years. 1 De Novo request was granted under it.

Definition

A Spinal Muscular Atrophy (SMA) newborn screening test system is a prescription device intended to detect homozygous deletion of exon 7 or other similar mutations in the SMN1 (Survival Motor Neuron 1) gene of DNA obtained from dried blood spot specimens on filter paper using a polymerase chain reaction-based test as an aid in screening newborns for SMA. Presumptive positive results are intended to be followed up by diagnostic confirmatory testing.

Classification

FieldValue
Device nameSpinal Muscular Atrophy Newborn Screening Test System
Device classClass II
Regulation21 CFR 866.5980
Review panelMG — Medical Genetics
Medical specialtyImmunology
Premarket route510(k)

510(k) clearances per year for QUE

YearClearancesAvg. review days
2026144

Compare with all 510(k) review times · Search every QUE clearance

Top QUE applicants

ApplicantClearancesLatest
Revvity, Inc.12026-09-30

Most recent QUE clearances

510(k)ApplicantDeviceDecision dateReview days
K262893Revvity, Inc.Eonis™ SMA kit2026-09-3044

Recalls for QUE devices

FDA recall records list no recalls for product code QUE.

Frequently asked questions

What is FDA product code QUE?

QUE is the FDA product code for spinal muscular atrophy newborn screening test system. It is a Class II device, regulated under 21 CFR 866.5980 and reviewed by the Medical Genetics panel.

What device class is QUE?

Class II, regulation 21 CFR 866.5980. Typical premarket route: 510(k).

How long does a 510(k) take for product code QUE?

Across 1 cleared submissions the average was 44 days from receipt to decision (median 44).

Which companies have the most QUE clearances?

Revvity, Inc. (1).

Next steps

Compiled by Caduvo from public U.S. FDA records. Applicant names are shown as FDA records them. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA. Not regulatory advice. Report an error. Data and corrections policy.

All Medical Genetics product codes · FDA product code lookup · 510(k) database search · 510(k) review times